Profile: Heartport provides technology that enables the surgeon to perform a wide variety of cardiac surgery via small incisions using minimally invasive techniques. This surgery uses minimally invasive techniques for coronary bypass grafting and mitral valve replacement. The endopulmonary bypass system is a catheter based system of devices that permits the heart to be arrested and maintain bypass. The system also includes specially designed long fine instruments enabling access to the surgical field. The endocoronary sinus catheter is inserted into the internal jugular or subclavian vein. This occludes the coronary sinus, monitoring coronary sinus pressure and central venous pressure (CVP) & delivers cardioplegia into the coronary sinus via a retrograde manner. The endopulmonary vent catheter is inserted via a neck vein into the pulmonary artery. This serves to remove blood from the pulmonary artery decompressing the heart. The endoarterial return cannula is inserted into the femoral artery. One arm returns oxygenated blood to the body and the other allows the passage of the endoaortic clamp catheter, allowing a single femoral incision. The endoaortic clamp catheter is used to occlude the ascending aorta.

The company has revenues of < USD 1 Million, has ~250 employees. NASDAQ:HPRT (SEC Filings)